Financial Performance - The group's revenue increased by approximately 2.5% from about HKD 70.2 million for the year ended March 31, 2021, to about HKD 72 million for the year ended March 31, 2022, primarily due to increased sales of medical gloves and biopsy needles [12]. - Gross profit rose by approximately HKD 2.7 million or 8.1% from about HKD 33.6 million for the year ended March 31, 2021, to about HKD 36.3 million for the year ended March 31, 2022, with the gross profit margin increasing from approximately 47.9% to about 50.5% [13]. - The group's profit decreased from approximately HKD 7,900,000 for the year ended March 31, 2021, to approximately HKD 4,000,000 for the year ended March 31, 2022, mainly due to increased employee costs and a one-time government subsidy in the previous year [18]. - The income tax expense for the year ended March 31, 2022, was approximately HKD 1.4 million, compared to about HKD 1.5 million in 2021 [15]. - The board declared an interim dividend of HKD 0.3 per share for the year ended March 31, 2022, down from HKD 0.45 per share in 2021 [19]. Operational Challenges and Strategies - The group continues to face challenges due to the significant impact of COVID-19 on the economy and customer spending plans [11]. - The group remains optimistic about the healthcare sector due to the growing elderly population and increasing medical awareness among Hong Kong citizens [8]. - The group is actively seeking suitable investment opportunities to diversify its business and enhance returns for shareholders [8]. - The group is focused on leveraging its strengths to diversify its product offerings and expand its customer base [8]. - The group plans to further expand its product portfolio and strengthen customer service to enhance its one-stop medical instrument solution services [11]. Human Resources and Employee Costs - Administrative and other operating expenses increased by approximately HKD 3.8 million or 15.2% from about HKD 25.4 million for the year ended March 31, 2021, to about HKD 29.2 million for the year ended March 31, 2022, mainly due to an increase in the number of employees [14]. - The group employed a total of 41 staff as of March 31, 2022, with employee costs amounting to approximately HKD 18,200,000, an increase from approximately HKD 15,600,000 in 2021 [34]. - The group is actively seeking strategic acquisition opportunities and has hired additional personnel to enhance product development capabilities [39]. Assets and Liabilities - As of March 31, 2022, current assets were approximately HKD 97,400,000, a decrease from approximately HKD 101,800,000 in 2021, while current liabilities decreased to approximately HKD 14,700,000 from HKD 17,500,000 [20]. - The group's cash and bank balances totaled approximately HKD 55,300,000 as of March 31, 2022, down from approximately HKD 70,200,000 in 2021 [21]. - Trade receivables increased to approximately HKD 17,300,000 as of March 31, 2022, compared to approximately HKD 7,700,000 in 2021 [22]. - The group had no significant debt financing, resulting in a debt-to-asset ratio of zero as of March 31, 2022 [23]. Corporate Governance - The company has adopted a new corporate governance code to enhance transparency and accountability, effective from January 1, 2022 [68]. - All directors confirmed compliance with trading standards and ethical guidelines, ensuring no violations occurred during the reporting period [70]. - The board consists of six directors responsible for overall business development goals and long-term company strategy [72]. - The company held four regular meetings and one annual general meeting during the fiscal year ending March 31, 2022 [75]. - The board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, to enhance governance [85]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to sustainable development, integrating environmental, social, and governance (ESG) principles into its business strategy to ensure long-term prosperity [146]. - The board of directors evaluates the potential impact of ESG issues on the overall strategy and monitors the company's performance in these areas [148]. - The company has established goals related to significant ESG issues and actively implements measures to enhance its performance in these areas [149]. - The group has established a working group to enhance employee awareness of environmental, social, and governance (ESG) issues, comprising senior management and staff from various departments [151]. - The ESG report focuses on the operations as a medical device distributor, which is the primary source of revenue for the group, and has expanded its reporting scope due to business growth [152]. Emissions and Resource Management - Direct greenhouse gas emissions (Scope 1) were 21 tons of CO2 equivalent, a decrease from 23 tons in the previous fiscal year [178]. - Total greenhouse gas emissions increased to approximately 53 tons of CO2 equivalent, up about 18% from 45 tons in the previous fiscal year [178]. - The total amount of non-hazardous waste generated was approximately 854 kilograms, an increase of about 15% from 740 kilograms in the previous fiscal year [183]. - The company has set a target to maintain or reduce non-hazardous waste density to approximately 11.86 kilograms per million revenue by the fiscal year 2030 [183]. - The company has implemented various energy and resource-saving measures to achieve its emission reduction goals [172].
君百延集团(08372) - 2022 - 年度财报